Join
Live feed
·
PRReleasevia Quantisnow
Acrivon Therapeutics Inc. logo

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11

ByQuantisnow·Wall Street's wire, on your screen.
ACRV· Acrivon Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACRV (Acrivon Therapeutics Inc.) and more on Quantisnow.